The Third International Stroke Trial: Thrombolysis (IST-3) in Poland: Are we recruiting the right patients?

Neurologia i Neurochirurgia Polska

Volumn 43, Issue 3, 2009, Pages 228-235

  Członkowska, Anna ^a,b   Kobayashi, Adam ^a   Lewis, Steff ^c   Sandercock, Peter ^c   Lindley, Richard ^d   Berańska Gieruszczak, Maria ^a   Bembenek, J ^a   Bilk, M ^a   Chabik, G ^a   Czepiel, W ^a   Gluskiewicz M ^a   Grabska, K ^a   Jedrzejewska, Julia ^a   Litwin, T ^a   Piorkowska A ^a   Skowronska M ^a   Sliwinska A ^a   Kotowicz, J ^e   Brodacki, B ^e   Staszewski, J ^e   Swistak J ^e   Richter, P ^a   Bochynska A ^a   Chahwan, M ^a   Graban, A ^a   Rola, R ^a   Nyka, W M ^f   Chowjnicki, K ^f   Gasecki, D ^f   Kozera, G ^f   Swierkocka M ^f   Opala, G ^g   Arkuszewski, M ^g   Pieta, M ^g   Swiat M ^g   more..

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

^e MILITARY INSTITUTE OF MEDICINE   (Poland)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

^g Central University Hospital   (Poland)

Author keywords

Randomized controlled trials; Stroke; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; FIBRINOLYTIC AGENT;

AGE DISTRIBUTION; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN REGION; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT CARE; PATIENT SELECTION; POLAND; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SEX RATIO; STROKE UNIT; TREATMENT INDICATION;

AGE DISTRIBUTION; AGED; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MEDICAL RECORDS; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 68149157417     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
2. Strong K., Mathers C., Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol 2007; 6: 182-187.
3. Czlonkowska A., Ryglewicz D., Weissbein T., et al. A prospective community-based study of stroke in Warsaw, Poland. Stroke 1994; 25: 547-551.
4. Cocho D., Belvis R., Marti-Fabregas J., et al. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 2005; 64: 719-720.
5. Qureshi A.I., Kirmani J.F., Sayed M.A., et al. Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. Neurology 2005; 64: 2115-2120.
6. Deng Y.Z., Reeves M.J., Jacobs B.S., et al. IV tissue plasminogen activator use in acute stroke: experience from a statewide registry. Neurology 2006; 66: 306-312.
7. Kapral M.K., Laupacis A., Phillips S.J., et al. Stroke care delivery in institutions participating in the Registry of the Canadian Stroke Network. Stroke 2004; 35: 1756-1762.
8. Heuschmann P.U., Berger K., Misselwitz B., et al. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke 2003; 34: 1106-1113.
9. Riks-Stroke; Swedish Stroke Register. 2008. Website: http://www.riks-stroke.org/index.php?content=&lang=eng&text= #name.
10. Wahlgren N., Ahmed N., Davalos A., et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282.
11. Sandercock P., Lindley R., Wardlaw J., et al. The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials 2008; 9: 37.
12. Sandercock P., Lindley R., Wardlaw J. Protocol 06PRT/1269: Third International Stroke Trial (IST-3). Lancet 2006. Website: www.thelancet.com.
13. Third International Stroke Trial open trial protocol, 2001. Website: www.ist3.com.
14. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
15. Hacke W., Kaste M., Fieschi C., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.
16. Hacke W., Kaste M., Fieschi C., et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-1251.
17. Clark W.M., Wissman S., Albers G.W., et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282: 2019-2026.
18. Hacke W., Kaste M., Bluhmki E., et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
19. Wardlaw J.M., Zoppo G., Yamaguchi T., et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003; (3): CD000213.
20. Hacke W., Donnan G., Fieschi C., et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-774.
21. Berrouschot J., Röther J., Glahn J., et al. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients. Stroke 2005; 36: 2421-2425.
22. Mouradian M.S., Senthilselvan A., Jickling G., et al. Intravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patients. J Neurol Neurosurg Psychiatry 2005; 76: 1234-1237.
23. Engelter S.T., Reichhart M., Sekoranja L., et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology 2005; 65: 1795-1798.
24. Tanne D., Gorman M.J., Bates V.E., et al. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience. Stroke 2000; 31: 370-375.
25. van Oostenbrugge R.J., Hupperts R.M., Lodder J. Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre. J Neurol Neurosurg Psychiatry 2006; 77: 375-377.
26. Demchuk A.M., Hill M.D., Barber P.A., et al. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA Stroke Study. Stroke 2005; 36: 2110-2115.
27. Dzialowski I., Hill M.D., Coutts S.B., et al. Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke 2006; 37: 973-978.
28. Fiorelli M., Bastianello S., von Kummer R., et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 1999; 30: 2280-2284.
29. Larrue V., von Kummer R.R., Muller A., et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001; 32: 438-441.
30. Wardlaw J.M., Mielke O. Early signs of brain infarction at CT: observer reliability and outcome after thrombolytic treatment - systematic review. Radiology 2005; 235: 444-453.
31. Weir N.U., Pexman J.H., Hill M.D., et al. How well does ASPECTS predict the outcome of acute stroke treated with IV tPA? Neurology 2006; 67: 516-518.
32. Barber P.A., Zhang J., Demchuk A.M., et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001; 56: 1015-1020.
33. Bray J.E., Coughlan K., Bladin C. Thrombolytic therapy for acute ischaemic stroke: successful implementation in an Australian tertiary hospital. Intern Med J 2006; 36: 483-488.
34. Kobayashi A., Skowronska M., Litwin T., et al. Lack of experience of intravenous thrombolysis for acute ischaemic stroke does not influence the proportion of patients treated. Emerg Med J 2007; 24: 96-99.
35. Litwin T., Kobayashi A., Skowronska M., et al. Thrombolysis in acute ischaemic stroke within 3 hours of symptom onset: a report of the first 100 cases. Neurol Neurochir Pol 2008; 42: 1-5.
36. Leys D., Ringelstein E.D., Kaste M., et al. Facilities available in European hospitals treating stroke patients. Stroke 2007; 38: 2985-2991.
37. Czlonkowska A., Sarzynska-Dlugosz I., Niewada M., et al. Eligibility of stroke units in Poland for administration of intravenous thrombolysis. Eur J Neurol 2006; 13: 220-224.
38. Weir N.U., Sandercock P.A., Lewis S.C., et al. Variations between countries in outcome after stroke in the International Stroke Trial (IST). Stroke 2001; 32: 1370-1377.
39. Niewada M., Skowronska M., Ryglewicz D., et al. Acute ischemic stroke care and outcome in centers participating in the Polish National Stroke Prevention and Treatment Registry. Stroke 2006; 37: 1837-1843.